Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Plans Phase III Program To Pick Up Obesity Claim For Victoza

This article was originally published in The Pink Sheet Daily

Executive Summary

Novo Nordisk is moving ahead with plans to develop Victoza (liraglutide) for obesity now that U.S. regulators are comfortable with the GLP-1's risk/benefit profile.
Advertisement

Related Content

Novo Is On Track To File Liraglutide For Obesity By 2014
Once-Weekly Insulin Added To Novo Nordisk’s Clinical Pipeline
Obesity Drug Developers Go With The Gut: R&D Hopes Focus On Locally Acting Agents
Obesity Drug Developers Go With The Gut: R&D Hopes Focus On Locally Acting Agents
FDA's Woodcock On Obesity Drugs: It's Hard To Fight Mother Nature
FDA's Woodcock On Obesity Drugs: It's Hard To Fight Mother Nature
Novo Nordisk's GLP-1 Victoza Off To A Good Start
Novo Nordisk's GLP-1 Victoza Off To A Good Start

Topics

Advertisement
UsernamePublicRestriction

Register

PS070795

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel